Video | May 22, 2020

Why Chimerix Pivoted To Take On COVID-19

Source: Life Science Leader

Rob Wright, chief editor of Life Science Leader, recently conducted a virtual roundtable with three CEOs of publicly traded biopharmaceutical companies (view full video here). In this clip, Mike Sherman, CEO of Chimerix (NASDAQ: CMRX), discusses the decision making behind an R&D pivot and the initiation of a Phase 2/3 study of dociparstat sodium (DSTAT) in acute lung injury for patients with severe COVID-19.